LENZ Therapeutics, Inc. (LENZ)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-11) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-24) · 99.1 | 8-K (2026-01-07) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-05) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-07-30) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-07) · 99.1 | 8-K (2025-04-15) | ||
| 10-K | FY-2024 | 8-K (2025-03-19) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-06) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-14) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-08) · 99.1 | ||
| 10-K | FY-2023 | — | ||
| 10-Q | Q3-2023 | — | ||
| 10-Q | Q2-2023 | — | ||
| 10-K/A | FY-2022 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Document and Entity Information | ||
| Audit Information | — |
|
| Statements | ||
| Balance Sheets | ||
| Consolidated Balance Sheets | ||
| Balance Sheets (P) | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Convertible Preferred and Common Stock and Stockholders' Equity | — |
|
| Condensed Consolidated Statements of Stockholders Equity | — |
|
| Condensed Statements of Stockholders' Equity (unaudited) | — |
|
| Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity Deficit | — |
|
| Condensed Consolidated Statements of Convertible Preferred and Common Stock and Stockholders' Equity (P) | — |
|
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Convertible Preferred and Common Stock and Stockholders' Equity (deficit) | ||
| Statements of Cash Flows | ||
| Consolidated Statements of Convertible Preferred and Common Stock and Stockholders' Equity (deficit) (P) | ||
| Notes | ||
| Accrued Liabilities | ||
| Balance Sheet Components | ||
| Commitments and Contingencies | ||
| Common Stock | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Description of Business, Organization and Liquidity | ||
| Employee Benefit Plan | — |
|
| Equity Incentive Plans | ||
| Fair Value Measurements | ||
| Fair Value of Financial Instruments | — |
|
| Financial Instruments | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Inventory | ||
| License Agreements | ||
| Marketable Securities | ||
| Merger and Related Transactions | ||
| Net Loss Per Share | ||
| Net Loss Per Share Attributable To Common Stockholders | ||
| Operating Leases | ||
| Organization and Liquidity | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment, Net | — |
|
| Related Party Transactions | ||
| Restructuring Activities | ||
| Share-based Compensation | — |
|
| Significant Agreements | ||
| Stockholders' Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||